Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lundbeck fine: industry outraged over messy patent system

This article was originally published in Scrip

Executive Summary

Lundbeck has branded as "erroneous" the European Commission's decision to fine it for anticompetitive behavior, while the European industry federation , EFPIA, has claimed that the affair flags up deficiencies in the European patent litigation system and raises cause for concern with implications for innovation, patient welfare and economic growth.

You may also be interested in...



EU Pay-For-Delay Ruling Against Lundbeck Sends Signal To Others, Including UK Competition Body

The EU’s General Court has upheld the European Commission’s decision to fine Lundbeck and a number of generics firms for agreeing to keep generic versions of the antidepressant citalopram off the market in return for payments. The ruling could have implications for other similar cases such as that involving GlaxoSmithKline’s paroxetine in the UK.

Big Pharma’s Aging Antibodies Cling To Their Crowns

The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?

Novartis To Pay $9.7bn For The Medicines Company

Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.

Related Companies

UsernamePublicRestriction

Register

SC021772

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel